

## Press Release

### Cellzome Appoints Prof. Tony Kouzarides and Dr. Peter Machin to Scientific Advisory Board

**Heidelberg, Germany, Cambridge, UK, 6<sup>th</sup> October 2010** - Cellzome, a leader in the use of chemical proteomics technologies to identify drug candidates for the treatment of inflammatory diseases, announces the appointment of two distinguished scientists to its Scientific Advisory Board (SAB) to advise on drug discovery in epigenetics. The appointments follow Cellzome's announcement earlier this year of a major collaboration with GSK in the field of epigenetics as applied to immuno-inflammatory disease.

**Prof. Tony Kouzarides** is an internationally recognized leader in the field of epigenetics and his research has led to fundamental insights into the function of chromatin modifications and their role in disease. He is a Royal Society Professor at the University of Cambridge and a member of the Science Strategy Advisory Group for Cancer Research UK and SAB member of several research institutes in Greece and Spain. Prof. Kouzarides has been awarded several international prizes for his research and is the author of more than 130 publications, many in high profile science journals.

**Dr Peter Machin** has more than thirty years experience of drug discovery and development in major pharmaceutical companies. He has held a number of senior positions at Roche, SmithKline Beecham and most recently, at GlaxoSmithKline where he was Global Senior Vice President of Discovery Research Chemistry. He has broad experience of lead discovery and optimisation through to development and has been responsible for the identification of a significant number of clinical candidates, across a wide range of therapeutic indications, two of which have reached market.

David Simmons, CSO of Cellzome and chairman of the SAB said:

"We are honoured, and it speaks volumes for the strength of our science, that these two distinguished individuals are joining our Scientific Advisory Board. Joining forces with Dr Machin and Prof. Kouzarides will significantly boost our efforts in the exciting new field of epigenetic drug discovery."

- ends -

**For more information please contact:**

**Cellzome:**

David Simmons  
CSO  
Tel: +49 (0) 6221-137 57-100  
press@cellzome.com

**Media contact:**

MHP Communications  
John Olsen  
Tel: +44 (0) 207 357 9477

## About Cellzome

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment of inflammatory diseases.

Our pipeline of small-molecule therapeutics is driven by *Kinobeads*<sup>™</sup>, a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called *Episphere*<sup>™</sup> to address epigenetic targets in disease-specific protein complexes. Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

Cellzome has two strategic alliances with GSK to discover and develop drugs to treat inflammatory diseases, the first in the field of kinase-targeted therapeutics and the second in the field of epigenetics.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two R&D laboratories in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: [www.cellzome.com](http://www.cellzome.com)

## SAB Full Biographies

**Prof. Tony Kouzarides** is an internationally recognized leader in the field of epigenetics and his research has led to fundamental insights into the function of chromatin modifications and their role in disease. Prof. Kouzarides is a Royal Society Professor at the University of Cambridge and Deputy Director of Gurdon Institute. He did his PhD at the University of Cambridge and after two postdoctoral fellowships at the MRC Laboratory of Molecular Biology in Cambridge and the New York University Medical Center, he started his independent research group and has been at the Gurdon Institute since 1991. Prof. Kouzarides is a member of the Science Strategy Advisory Group for Cancer Research UK and SAB member of several research institutes in Greece and Spain. Prof. Kouzarides is a member of the European Molecular Biology organization, the British Academy of Medical Sciences and has additionally been awarded several prestigious international prizes for his research. He is the author of more than 130 publications in research journals. Prof. Kouzarides is also the founder and director of "Vencer el Cancer" (Conquer Cancer), a charity based in Spain which raises public funds for cancer research and anti-cancer drug discovery.

**Dr Peter Machin** FRSC FMedSci has more than thirty years experience of drug discovery and development in major pharmaceutical companies. He has held a number of senior positions; at Roche as head of chemistry in the UK, then at SmithKline Beecham as Vice President of Discovery Chemistry Europe and most recently, as Global Senior Vice President of Discovery Research Chemistry at GlaxoSmithKline. He has broad experience of lead discovery and optimisation through to development and has been responsible for the identification of a significant number of clinical candidates, across a wide range of therapeutic indications, two of which have reached market. Peter Machin gained his PhD in organic chemistry from Imperial College, London. He is a Fellow of the Academy of Medical Sciences and is Honorary Treasurer of the Royal Society of Chemistry.